ALDH1A3 and cancer: The fact that ALDH1A3 knockdown sensitizes cancer cells to therapy [37,41,51,64,68,69] further supports the need for the development of clinical ALDH1A3 inhibitors as adjuvant therapies (discussed later in this review).